Emergency Use Authorization
Overview and Considerations for COVID-19 Vaccines

Maria Allende, MD
Chief, Clinical Review Branch 1, Division of Vaccines and Related Products Applications, Office of Vaccines Research and Review, Center for Biologics Evaluation and Research, FDA
February 26, 2021
Introduction

• The COVID-19 pandemic continues in the U.S. and world-wide
  – >28 million cases, >500,000 deaths in U.S. to date*
  – >400,000 new cases, >2,000 deaths in U.S. in the week ending February 24, 2021*

• On December 11, 2020, FDA issued an Emergency Use Authorization (EUA) for the Pfizer-BioNTech COVID-19 vaccine, for prevention of COVID-19 disease due to SARS-CoV-2 in individuals 16 years of age and older

• On December 18, 2020, and EUA was issued for the Moderna COVID-19 vaccine for prevention of COVID-19 disease in individuals 18 years of age and older

• Both of these COVID-19 vaccines remain unapproved products and are not available in sufficient quantities to address public health needs; thus, there is no adequate, approved, and available alternative in the US for prevention of COVID-19

*Centers for Disease Control and Prevention, https://covid.cdc.gov/covid-data-tracker/
Janssen’s EUA Request

  – Ad26.COV2.S vaccine administered as a 1 dose regimen
  – Requested use is for active immunization to prevent COVID-19 caused by SARS-CoV-2 in individuals 18 years of age and older
  – Information submitted with the request includes safety and efficacy data from a large (N>43,000) randomized, blinded, placebo-controlled Phase 3 trial COV3001 (ENSEMBLE)
  – Participants were enrolled from 8 countries: United States, Argentina, Brazil, Chile, Colombia, Mexico, Peru and South Africa
FDA Review of Janssen’s EUA Request

• FDA has been conducting a comprehensive review of the Janssen COVID-19 vaccine EUA submission received on February 4, 2021, including:
  – Verification of clinical data integrity and Janssen’s analyses, and additional FDA analyses, from datasets provided in the submission
  – Ongoing review of manufacturing, non-clinical, and clinical assay information
  – Review and revision of prescribing information and fact sheets for vaccine recipients and healthcare providers
  – Multiple information requests to Janssen to address questions and clarifications
  – Preparation for today’s VRBPAC meeting

• Today’s VRBPAC meeting continues FDA’s commitment to an expedited review process that is transparent, scientifically sound, and data-driven
EUA Legal Authority

- Established in Section 564 of the Federal Food, Drug, and Cosmetic Act
- Allows for FDA authorization of unapproved medical products (or unapproved uses of approved medical products) to address public health emergencies related to biological, chemical, radiological, or nuclear agents
- Requires prior determination of a threat, and declaration of circumstances justifying need for EUA to address that threat, by the Secretary of Homeland Security, Defense, or Health and Human Services
  - HHS Secretary issued a declaration on March 27, 2020, justifying EUA of drugs and biological products to address the COVID-19 pandemic
Criteria for FDA Issuance of EUA

• The agent referred to in the EUA declaration can cause a serious or life-threatening disease or condition

• The known and potential benefits of the product outweigh the known and potential risks of the product

• No adequate, approved, and available alternative to the product for diagnosing, preventing, or treating the disease or condition

  – The Pfizer-BioNTech COVID-19 and Moderna vaccines are available under EUA for prevention of COVID-19 but remain unapproved (and quantity available for mass vaccination is limited)
COVID-19 Vaccine EUA - FDA Expectations

- FDA expectations were discussed in detail at October 22, 2020, and December 10 & 17, 2020, VRBPAC meetings and described in FDA Guidance, [Emergency Use Authorization for Vaccines to Prevent COVID-19](https://www.fda.gov/emergency-preparedness-operations/provisional-authorizations-emergency-use-authorization)
  
  - Data to demonstrate manufacturing quality and consistency
  
  - Clear and compelling safety and efficacy data to support favorable benefit-risk of the vaccine when rapidly deployed for administration to millions of individuals, including healthy people
  
  - Plans for further evaluation of vaccine safety and effectiveness, including in ongoing clinical trials, active and passive safety monitoring during use under EUA, and observational studies
Issuance of EUA for a COVID-19 Vaccine

• Will specify conditions of use for which benefit-risk has been determined to be favorable based on review of available data

• Will provide information to vaccine recipients and healthcare providers by way of prescribing information and fact sheets

• EUA may be revised or revoked if other circumstances arise that warrant changes necessary to protect public health or safety, e.g. based on new information
VRBPAC Agenda

- Epidemiology of COVID-19 Variants and Postmarketing Surveillance from currently authorized COVID-19 vaccines- (CDC and FDA)
- 11AM Break (10 minutes)
- Sponsor Presentation (Janssen)
- Lunch break (30 minutes)
- Open Public Hearing
- FDA presentation and Voting Question
- Committee Discussion and Voting
Question for VRBPAC Vote (yes/no)

Based on the totality of scientific evidence available, do the benefits of the Janssen COVID-19 Vaccine outweigh its risks for use in individuals 18 years of age and older?
FDA Expectations for Clinical Data

• Efficacy data from at least one well-designed Phase 3 trial demonstrating protection against SARS-CoV-2 infection or disease:
  – Point estimate of least 50% vs. placebo comparator
  – Appropriately alpha-adjusted confidence interval lower bound >30%

• Safety data from throughout clinical development to evaluate reactogenicity, serious AEs, and AEs of special interest
  – Including a high proportion of Phase 3 study subjects followed for at least 1 month after completion of the full vaccination regimen

• Sufficient cases of severe COVID-19 to assess for signals of enhanced disease (and preliminary evidence of protection against severe disease)
FDA Expectations for Clinical Data

• A planned case-driven interim efficacy analysis and associated safety analyses could provide data to support an EUA
  – These analyses should include a median follow-up duration of at least 2 months after completion of the full vaccination regimen

• Reasons for expectation of 2 months median follow-up:
  – Allows time for potential immune-mediated adverse reactions to be evaluated (uncommon but clinically significant immune-mediated adverse reactions to preventive vaccines generally have onset within 6 weeks following vaccination)
  – Ensures that vaccine efficacy is assessed during the time when adaptive/memory immune responses (rather than innate responses) are mediating protection
  – Allows for early assessment of waning protection and signals of enhanced disease
FDA Expectations for Further Evaluation

• Following issuance of an EUA, further vaccine evaluation would be needed:
  – For ongoing benefit/risk assessment to support continuation of the EUA
  – To accrue additional data to support licensure as soon as possible and/or to inform labeling

• Further vaccine evaluation following issuance of an EUA would include:
  – Longer-term follow-up for safety, including in larger numbers of vaccine recipients and in populations with lower representation in clinical trials
  – More precise estimation of vaccine effectiveness in specific populations
  – More robust assessment of effectiveness against aspects of SARS-CoV-2 infection or disease
  – Characterization of duration of protection
  – Assessment of effectiveness against relevant circulating strains
  – Investigation of immune biomarkers that might predict protection
  – Ongoing monitoring for signals of enhanced disease
FDA Expectations for Further Evaluation

- Issuance of an EUA for a COVID-19 vaccine would be contingent upon the ability to conduct further vaccine evaluation through a combination of:
  - Active follow-up of vaccine recipients under the EUA
  - Passive monitoring for clinically significant adverse reactions using established reporting mechanisms (e.g., VAERS)
  - Observational studies, including those that leverage healthcare claims databases
  - Continuation of blinded, placebo-controlled follow-up in ongoing clinical trials for as long as is feasible and strategies to handle loss of follow-up
  - Trial participants may choose to withdraw from follow-up for any reason, including to receive vaccine made available under EUA
COVID-19 Vaccines under EUA

• The mRNA-based BNT162b2 vaccine from Pfizer and BioNTech is authorized under an EUA for active immunization for the prevention of COVID-19 caused by SARS-CoV-2 in individuals ≥16 years of age, administered as 2 doses 3 weeks apart. Among participants without evidence of SARS-CoV-2 infection before and during vaccination regimen, VE for the first primary endpoint against confirmed COVID-19 occurring at least 7 days after the 2nd dose was 95.0%.

• The mRNA-1273 vaccine from Moderna Inc is authorized for use under an EUA for active immunization to prevent COVID-19 caused by SARS-CoV-2 in adults ≥18 years of age. The vaccine is administered as 2 doses 4 weeks apart. Among participants without history of SARS-CoV-2, VE for the primary endpoint against symptomatic COVID-19 (confirmed by an adjudication committee) occurring at least 14 days after the 2nd dose was 94.1%.
COVID-19 Vaccinations in the United States*

• Number of people receiving 1 or more doses
  – 44,544,969 (13% of the population)

• Number of people receiving 2 doses
  – 19,882,544 (6% of the population)

• Total Doses Administered
  – 65,032,083